Evidence map›Paper›PMID 39404162›Full record

ArticleJournal of medicinal chemistry2024

Pyrazolo-Pyrimidinones with Improved Solubility and Selective Inhibition of Adenylyl Cyclase Type 1 Activity for Treatment of Inflammatory Pain.

Annadka Shrinidhi, Tiffany S Dwyer, Jason A Scott, Val J Watts, Daniel P Flaherty

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. CaMolecular pharmacology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Annadka ShrinidhiBorch Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States.ORCID 0000-0003-1022-617X
Tiffany S DwyerBorch Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States.ORCID 0009-0002-7863-5412
Jason A ScottBorch Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States.
Val J WattsBorch Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States.ORCID 0000-0003-1581-2936
Daniel P FlahertyBorch Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907, United States.ORCID 0000-0002-8305-0606

Funding

KATP Channels as Downstream targets of adenylyl cyclases during opioid tolerance and withdrawalR01DA051876 · NIDA · UNIVERSITY OF MINNESOTA · PI KLEIN, AMANDA HELEN · 2021 to 2025
$2.9M
Pharmacological validation of adenylyl cyclase 1 as a drug target for chronic painR01NS119917 · NINDS · PURDUE UNIVERSITY · PI FLAHERTY, DANIEL PATRICK, WATTS, VAL J · 2021 to 2025
$2.0M
NIDA NIH HHS R01 DA051876NINDS NIH HHS R01 NS119917
6 · The paper itself

Abstract

Adenylyl cyclase isoform 1 (AC1) is considered a promising target for treating inflammatory pain. Our group identified the pyrazolyl-pyrimidinone scaffold as potent and selective inhibitors of Ca

Indexed as

Adenylyl CyclasesInflammationPainPyrazolesPyrimidinonesSolubilityAdenylyl Cyclase InhibitorsAnimalsFreund's AdjuvantHumansMaleRatsRats, Sprague-DawleyStructure-Activity Relationshipadenylyl cyclase 1Adenylyl Cyclase InhibitorsAdenylyl CyclasesFreund's AdjuvantPyrazolesPyrimidinones

Identifiers

PMID39404162
PMCPMC12172514

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.